Spokane Urology — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$450,044	59
2024	Research	$719,893	66
2023	Research	$141,313	34
2022	Research	$102,865	48
2021	Research	$57,675	12

Breakdown

Who paid Research payments · program years 2021–2025

Janssen Research & Development, LLC $1,234,069 191 payments
AstraZeneca Pharmaceuticals LP $84,708 1 payment
Urogen Pharma, Inc. $77,122 26 payments
Merck Sharp & Dohme Corporation $75,891 1 payment

Studies the money was for Research payments · program years 2021–2025

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc $731,870 73 payments
A Multi Center Open label Single arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy ADT in Treatment naive Participants Who Have Undergone Radical Prostatectomy RP for Nonmetastatic Prostate Cancer and Who Are at High Risk for Metastases $119,777 57 payments
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco $84,708 1 payment
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor $75,891 1 payment
Bl011 - A Phase 3 Single-Arm Study of Ugn -102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (Envision) $73,301 20 payments
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo $68,254 19 payments
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc $66,447 11 payments
A Multi Center Open label Single arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy ADT in Treatment naive Participants Who Have Undergone Radical Prostatectomy RP for Nonmetastatic Prostate Cancer and Who Are at Hi $57,675 12 payments
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) $49,819 6 payments
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGu?rin (BCG) in Participants with BCG-na?ve High-Risk Non-Muscle Invasive Bladder Canc $39,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.